Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Win-K Cells** is a Wincell Research autologous cellular immunotherapy product composed of natural killer cells, cytokine-induced killer cells, and T cells expanded from the recipient's blood. The product is intended to augment immune-mediated recognition and destruction of cancer cells and virus-infected cells, and Wincell describes its use alongside standard cancer treatments and, in some settings, with its WT1-pulsed dendritic-cell cancer vaccine. Publicly available sponsor material does not specify a clinical development phase, cell-manufacturing specifications, or a disease-specific regulatory approval. ([wincellresearch.com](https://www.wincellresearch.com/en/service/win-k-cells-lak-cells/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Win-K Cells.